Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LEXXW 
Lexaria Bioscience Corp (LEXXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LEXXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -16.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 |
52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1581.04% |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -145.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16302820 |
Shares Outstanding - | Shares Floating 16302820 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2014. They focus on developing and out-licensing their DehydraTECH drug delivery technology.
Core Business Areas
- DehydraTECH Technology Licensing: Lexaria's primary business is licensing its DehydraTECH technology, which enhances the bioavailability of active pharmaceutical ingredients (APIs).
- Drug Development Programs: Lexaria also develops its own drug formulations using DehydraTECH, targeting indications like hypertension and neurological diseases.
Leadership and Structure
Chris Bunka is the CEO. The company has a board of directors and a management team focused on research, development, and licensing.
Top Products and Market Share
Key Offerings
- DehydraTECH Technology: DehydraTECH is Lexaria's patented drug delivery platform. Revenue comes from licensing agreements. Competitors are companies with alternative drug delivery systems such as nanoemulsions or liposomes, or generic alternatives for particular treatments.
- DehydraTECH-CBD for Hypertension: Lexaria is developing formulations for hypertension, using DehydraTECH-CBD. Market share is not yet applicable as the product is still in clinical trials. Competitors are pharmaceutical companies developing hypertension drugs.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth in drug delivery technologies that enhance bioavailability and efficacy. The market for hypertension treatments is substantial.
Positioning
Lexaria positions itself as an innovator in drug delivery with DehydraTECH. Its advantage lies in its patented technology and its potential to improve drug efficacy and reduce dosages.
Total Addressable Market (TAM)
The global hypertension treatment market is projected to be worth hundreds of billions of dollars. Lexaria is positioned to capture a portion of this market through its DehydraTECH-CBD based solutions. TAM for improved drug delivery technology across all applications is also a multibillion market.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECH technology
- Potential for enhanced bioavailability
- Proprietary drug development programs
- Experienced management team
Weaknesses
- Limited revenue generation to date
- Reliance on licensing agreements
- Clinical trial risks
- Small market capitalization
Opportunities
- Expanding licensing agreements
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Market growth in drug delivery technologies
Threats
- Competition from established drug delivery companies
- Regulatory hurdles
- Failure to achieve clinical trial endpoints
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- ABBV
Competitive Landscape
Lexaria faces competition from larger pharmaceutical companies with established drug delivery systems. Its advantage lies in the potential of DehydraTECH to offer improved bioavailability and efficacy.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by progress in clinical trials and the signing of new licensing agreements.
Future Projections: Future growth depends on successful clinical trials and increased adoption of DehydraTECH technology. Analyst estimates vary widely due to the inherent uncertainty in the biotech industry.
Recent Initiatives: Recent initiatives include advancing clinical trials for DehydraTECH-CBD in hypertension and exploring new applications for DehydraTECH.
Summary
Lexaria Bioscience is a micro-cap company that is high risk and high reward. Their DehydraTECH platform has the potential to disrupt the space with its ability to increase bioavailability, but clinical trials are necessary to prove its worth. They are not revenue-generating and are dependent on capital raises. Investors should be aware of the substantial risks and possible long-term timeline to commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. SEC Filings
- Lexaria Bioscience Corp. Investor Presentations
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2021-01-12 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.